Literature DB >> 28732619

Endophthalmitis prophylaxis by intracameral antibiotics: In vitro model comparing vancomycin, cefuroxime, and moxifloxacin.

Peter E Libre1, Sean Mathews2.   

Abstract

PURPOSE: To compare the efficacy of intracameral vancomycin, cefuroxime, and moxifloxacin on postoperative bacterial endophthalmitis rates.
SETTING: Norwalk Hospital, Norwalk, Connecticut, USA.
DESIGN: Experimental study.
METHODS: Bacteria and intraocular lenses (IOLs) were incubated with vancomycin, cefuroxime, moxifloxacin, or combinations. Antibiotic concentrations were high, corresponding to clinical maximum intracameral doses (1.0 mg vancomycin or cefuroxime, 0.5 mg moxifloxacin), or low (one third of clinical maximum dose). The following bacteria were isolated from patients with endophthalmitis: 18 strains including 6 staphylococci, 6 streptococci, 3 pseudomonad, and 3 propionibacteria. Samples were diluted by half every 2 hours to model the half-life of intracameral antibiotics. At 24 hours, samples were vortexed to shake bacterial biofilms loose from the IOLs. The bacterial broth was plated and colonies were counted 24 hours later.
RESULTS: Efficacy against staphylococci was concentration dependent; all antibiotics were effective at high concentrations, while low concentrations were in general ineffective. Streptococci and propionibacteria were nearly eliminated by all antibiotics at low concentrations. Pseudomonads were most effectively treated by high-dose moxifloxacin and its combinations.
CONCLUSIONS: Broadest coverage against common pathogens should be obtained by high-dose moxifloxacin (0.5 mg intracameral). Submaximum dosing, which could occur if aqueous is released to lower intraocular pressure after injection, compromises the efficacy against staphylococci and pseudomonads. All antibiotics, even at low doses, were effective against streptococci and propionibacteria, suggesting that many of the worst endophthalmitis outcomes could be prevented by intracameral use of any of the 3 antibiotics used in this study.
Copyright © 2017 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28732619     DOI: 10.1016/j.jcrs.2017.04.028

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  6 in total

1.  Injection volume and intracameral moxifloxacin dose.

Authors:  Neal H Shorstein; Susanne Gardner
Journal:  J Cataract Refract Surg       Date:  2019-08-20       Impact factor: 3.351

2.  Surgical Antimicrobial Prophylaxis in Patients of Neonatal and Pediatric Age Subjected to Eye Surgery: A RAND/UCLA Appropriateness Method Consensus Study.

Authors:  Sonia Bianchini; Chiara Morini; Laura Nicoletti; Sara Monaco; Erika Rigotti; Caterina Caminiti; Giorgio Conti; Maia De Luca; Daniele Donà; Giuseppe Maglietta; Laura Lancella; Andrea Lo Vecchio; Giorgio Marchini; Carlo Pietrasanta; Nicola Principi; Alessandro Simonini; Elisabetta Venturini; Rosa Longo; Elena Gusson; Domenico Boccuzzi; Luca Vigo; Fabio Mosca; Annamaria Staiano; Susanna Esposito
Journal:  Antibiotics (Basel)       Date:  2022-04-22

3.  Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery.

Authors:  Neal H Shorstein; Liyan Liu; James A Carolan; Lisa Herrinton
Journal:  Am J Ophthalmol       Date:  2021-02-08       Impact factor: 5.488

4.  Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells.

Authors:  Hitomi Miyake; Dai Miyazaki; Yumiko Shimizu; Shin-Ichi Sasaki; Takashi Baba; Yoshitsugu Inoue; Kazuki Matsuura
Journal:  Sci Rep       Date:  2019-07-05       Impact factor: 4.379

5.  Endophthalmitis following cataract surgery and intracameral antibiotic: Moxifloxacin resistant Staphylococcus epidermidis.

Authors:  Victoria S Chang; Stephen G Schwartz; Janet L Davis; Harry W Flynn
Journal:  Am J Ophthalmol Case Rep       Date:  2018-12-08

6.  Postoperative endophthalmitis with and without intracameral moxifloxacin prophylaxis in a high volume surgery setting.

Authors:  Subash Bhatta; Nayana Pant; Manish Poudel
Journal:  BMJ Open Ophthalmol       Date:  2021-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.